Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab

Immune check point inhibitors (ICIs) have shown remarkable success in medical oncology and are being used in many types of tumours including non –small-cell lung carcinoma (NSCLC). However, activation of host T cells can cause immune-related adverse events (irAEs), which can make treatment decisions difficult. Immune-related liver injury is a common form of irAEs and is known to occur in 1–3% of patients treated with ICIs [1]. In contras t, only eight cases of immune-related cholangitis have been reported, most of whom required extensive treatment [2–7].

Source: European Journal of Cancer - December 13, 2018 Category: Cancer & Oncology Authors: Shoko Noda-Narita, Suguru Mizuno, Satoshi Noguchi, Kousuke Watanabe, Yousuke Nakai, Kazuhiko Koike, Hidenori Kage, Takahide Nagase Tags: Letter to the Editor Source Type: research